Compare KD & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KD | ATAI |
|---|---|---|
| Founded | 2020 | 2018 |
| Country | United States | United States |
| Employees | 80000 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.7B |
| IPO Year | 2021 | 2025 |
| Metric | KD | ATAI |
|---|---|---|
| Price | $13.30 | $7.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 8 |
| Target Price | ★ $25.92 | $15.88 |
| AVG Volume (30 Days) | 3.6M | ★ 6.6M |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,092,000,000.00 | $4,089,000.00 |
| Revenue This Year | $3.73 | N/A |
| Revenue Next Year | $0.08 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 0.23 | ★ 1227.60 |
| 52 Week Low | $10.10 | $3.27 |
| 52 Week High | $33.90 | $7.45 |
| Indicator | KD | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 54.44 | 66.46 |
| Support Level | $13.14 | $3.56 |
| Resistance Level | $13.81 | N/A |
| Average True Range (ATR) | 0.54 | 0.07 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 76.09 | 54.76 |
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives. The company's reportable segments consist of the following: Principal Markets which represents its operations in operations in, Canada, France, Germany, India, Italy, Spain, Portugal, and the United Kingdom / Ireland, United States, Japan, and Strategic Markets. It derives maximum revenue from the United States.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.